LIVERSTAT for risk stratification for patients with metabolic dysfunction-associated fatty liver disease

Leow YW 1 , Chan WL 1 , Lai LL 1 , Mustapha NRN 2 , Mahadeva S 1 , Quiambao R 3 Show all authors , Munteanu M 3 , Chan WK 1

Affiliations 

  • 1 Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
  • 2 Department of Pathology, Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia
  • 3 Medical Affairs, Fibronostics US Inc., Indian Harbour Beach, Florida, USA
J Gastroenterol Hepatol, 2024 Jul 01.
PMID: 38946405 DOI: 10.1111/jgh.16675

Abstract

BACKGROUND AND AIM: LIVERSTAT is an artificial intelligence-based noninvasive test devised to screen for and provide risk stratification for metabolic dysfunction-associated fatty liver disease (MAFLD) by using simple blood biomarkers and anthropometric measurements. We aimed to study LIVERSTAT in patients with MAFLD and to explore its role for the diagnosis of advanced fibrosis.

METHODS: This is a retrospective study of data from MAFLD patients who underwent a liver biopsy. Patients with type 2 diabetes who underwent transient elastography and had liver stiffness measurement (LSM) 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications